CO-Qo-ICU

France
|
2020-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome

Balsano

Italy
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome

Cov-N-Psy

Belgium
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome

Yildiz

Türkiye
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome

COMEBAC 2

France
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome

Andreasson

Sweden
|
2021-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Community
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome
  • Blood sample

Bridevaux

Switzerland
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome

Aguilaniu

Canada France Martinique Switzerland
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome

DisCOVID

France
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome

FAPI CLIMATE

Netherlands
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition
  • Post-acute infection syndrome
  • Blood sample

Orth

Germany
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Cuadrado-Payán

Spain
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir